Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to commercial execution and customer onboarding for this group.
Is now the time to buy PODD? Find out in our full research report (it’s free for active Edge members).
Insulet (PODD) Q2 CY2026 Highlights:
- Revenue: $801.7 million vs analyst estimates of $787.1 million (23.5% year-on-year growth, 1.9% beat)
- Adjusted EPS: $1.66 vs analyst estimates of $1.45 (14.3% beat)
- Adjusted EBITDA: $199.8 million vs analyst estimates of $187 million (24.9% margin, 6.8% beat)
- Revenue Guidance for Q3 CY2026 is $833.4 million at the midpoint, below analyst estimates of $847.3 million
- Operating Margin: 16.2%, down from 18.7% in the same quarter last year
- Constant Currency Revenue rose 22.7% year on year (31.3% in the same quarter last year)
- Market Capitalization: $10.04 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Insulet’s Q2 Earnings Call
- Robert Marcus (JPMorgan) asked what changed since previous positive commentary on type 2 and how management accounts for increased competition. CEO Ashley McEvoy admitted, “we should have understood some of these type 2 trends sooner,” and clarified guidance assumes stable pricing and no immediate improvement from current initiatives.
- Travis Steed (Bank of America) questioned the assumptions for U.S. Omnipod growth and timeline for stabilization in type 2 retention. CFO Flavia Pease responded that guidance reflects a “prudent approach” and includes a range for possible outcomes, with new product launches factored in.
- Larry Biegelsen (Wells Fargo) asked why management is confident new initiatives will improve retention. McEvoy pointed to the size and unmet need in type 2, while COO Eric Benjamin cited success with pilot programs and early positive data from Omnipod Discover.
- Jeffrey Johnson (Baird) inquired about pricing dynamics and the effectiveness of efforts to re-engage lapsed users. McEvoy described disciplined pricing and expanding coverage, while Benjamin detailed scaling up personalized support programs shown to improve retention.
- Kieran Ryan (Deutsche Bank) sought clarity on whether retention or utilization was the bigger issue and how prescriber type affects outcomes. McEvoy stated retention is the main concern and noted higher retention among patients managed by endocrinologists, with expanded outreach to primary care as a strategic priority.
Catalysts in Upcoming Quarters
Looking ahead, our team will watch (1) whether Insulet’s onboarding and support initiatives for type 2 customers translate into improved retention, (2) the pace of international expansion and Omnipod adoption in new markets like Spain, and (3) progress on the pipeline, particularly the development timelines for Omnipod 6 and the fully closed-loop system for type 2 diabetes. Execution on these priorities will be key to restoring investor confidence.
Insulet currently trades at $143.83, down from $166.82 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
